

IN THE UNITED STATES RECEIVING OFFICE
PATENT COOPERATION TREATY

Application No. : 10/550,721
Confirmation No. : 5507
Applicant : Rolph et al.
371(c) Date : July 17, 2006
Group Art Unit : Not yet assigned
Examiner: : Not yet assigned
Docket No. : 007193-12
Customer No. : 36,234

I hereby certify that, on the date shown below, this correspondence, along with any document stated as being enclosed, is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Stop PCT, Commissioner for Patents, PO Box 1450, Alexandria VA 22313-1450

Date: 3/8/07


Greg McCallum

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Dear Sir:

The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits, whichever event occurs last. 37 C.F.R. Section 1.97(b).


Enclosed is Form 1449 and 94 foreign and non-patent references. Applicants respectfully request that each of the cited information be expressly considered during the prosecution of this application and that the cited references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. If required, a copy of each reference is attached.

FEES

It is believed no fee is due. If any fee is due, please charge Deposit Account No. 502679.

Date

3/8/07


Jennifer M. McCallum, Ph.D., Esq.

Reg. No.: 52,492

Tel. No.: 303-828-0655

Fax No.: 303-828-2938

Customer No.: 36234

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/550,721
	Filing Date	03/26/2004
	First Named Inventor	Michael Rolph
	Art Unit	Unknown
	Examiner Name	Unknown
Sheet 1 of 6	Attorney Docket Number	007193-12

U.S. Patent Documents					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	2003/0036070 A1	02-20-2003	Chakravarti	
	2	4,016,043	04-05-1977	Schuurs et al.	
	3	4,018,653	04-19-1977	Mennen et al.	
	4	4,366,241	12-28-1982	Tom et al.	
	5	4,424,279	01-03-1984	Bohn et al.	
	6	4,683,195	07-28-1987	Mullis et al.	
	7	4,843,000	06-27-1989	Litman et al.	
	8	4,849,338	07-18-1989	Litman et al.	
	9	5,227,487	07-13-1993	Haugland et al.	
	10	5,274,113	12-28-1993	Kang et al.	
	11	5,326,692	07-05-1994	Brinkley et al.	
	12	5,405,975	04-11-1995	Kuhn et al.	
	13	5,433,896	07-18-1995	Kang et al.	
	14	5,442,045	08-15-1995	Haugland et al.	
	15	5,451,663	09-19-1995	Kang et al.	
	16	5,453,517	09-26-1995	Kuhn et al.	
	17	5,459,276	10-17-1995	Kuhn et al.	
	18	5,516,864	05-14-1996	Kuhn et al.	
	19	5,550,050	08-27-1996	Holland et al.	
	20	5,573,909	11-12-1996	Singer et al.	
	21	5,648,270	07-15-1997	Kuhn et al.	
	22	5,691,198	11-25-97	Jin et al.	
	23	5,723,218	03-03-1998	Haugland et al.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/550,721
	Filing Date	03/26/2004
	First Named Inventor	Michael Rolph
	Art Unit	Unknown
	Examiner Name	Unknown
Sheet 2 of 6	Attorney Docket Number	007193-12

Foreign Patent Documents					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	24	EP 0425731 B1	01-19-1994	Siemens Aktiengesellschaft	
	25	EP 1234878 A1	08-28-2002	Takeda Chemical Industries, Ltd.	
	26	WO 84/03564 A1	09-13-1984	Commonwealth Serum Labs	
	27	WO 90/07936 A1	07-26-1990	Chiron Corp.	
	28	WO 92/19195 A1	11-12-1992	Brown Univ. Res. Foundation	
	29	WO 93/06121 A1	04-01-1993	Affymax Technologies	
	30	WO 94/25503 A6	11-10-1994	Cytotherapeutics, Inc.	
	31	WO 95/01203 A3	01-12-1995	Cytotherapeutics, Inc.	
	32	WO 95/05452 A3	02-23-1995	Cytotherapeutics, Inc.	
	33	WO 96/02286 A1	02-01-1996	Cytotherapeutics, Inc.	
	34	WO 96/02646 A2	02-01-1996	Cytotherapeutics, Inc.	
	35	WO 96/11698 A1	04-25-1996	Symphony Pharm. Inc.	
	36	WO 96/40871	12-19-1996	Cytotherapeutics, Inc.	
	37	WO 96/40959 A1	12-19-1996	Cytotherapeutics, Inc.	
	38	WO 97/02048 A1	01-23-1997	Millenium Pharm. Inc.	
	39	WO 97/12635 A1	04-10-1997	Cytotherapeutics, Inc.	
	40	WO 00/29621 A2	05-25-2000	Genelabs Tech, Inc.	
	41	WO 00/59506 A1	10-12-2000	Bristol-Meyers Squibb Co.	
	42	WO 02/062848 A2	08-15-2002	Children's Hospital Med Cntr	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/550,721
	Filing Date	03/26/2004
	First Named Inventor	Michael Rolph
	Art Unit	Unknown
	Examiner Name	Unknown
Sheet 3 of 6	Attorney Docket Number	007193-12

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or county where published.	T ²
	43	Bandyopadhyay et al, <i>Mol. Cell. Biol.</i> 4(4): 749-754, 1984	
	44	Baugh et al., <i>Nucleic Acids</i> 29(5): E29, 1-9, 2001	
	45	Baxa, C. A. et al., <i>Biochemistry</i> 1989, 28(22): 8683-8690. (Abstract and Sequence Listing)	
	46	Beasley, <i>Lancet</i> 351(9111):1225-1232, 1998	
	47	Berglund et al., <i>Biotechnology</i> 11: 916-920, 1993	
	48	Berkner et al., <i>BioTechniques</i> 6: 616-629, 1988	
	49	Berkner, <i>Curr. Top. Microbiol. Immunol.</i> 158: 39-66, 1992	
	50	Breakefield, <i>Mol. Neurobiol.</i> 1: 339-371, 1987	
	51	Buchsacher, <i>J. Virol.</i> 66(5): 2731-2739, 1992	
	52	Davies, <i>Curr. Opin. Allergy Clin. Immunol.</i> 1(1): 67-71, 2001	
	53	EMBL, ID HSALBP, Human adipocyte lipid-binding protein, complete cds. Baxa, C.A., et al.	
	54	EMBL, ID HSFABPHA, Human fatty acid binding protein homologue (PA-FABP)mRNA, complete cds. Madsen, P., et al.	
	55	Erickson et al., <i>Science</i> 249: 527-533, 1990	
	56	Fink et al., <i>Ann. Rev. Neurosci.</i> 19: 265-287, 1996	
	57	Fink et al., <i>Hum. Gene Ther.</i> 3: 11-19, 1992	
	58	Finkelman et al., <i>J. Immunol.</i> 141(7): 2335-2341, 1988	
	59	Fodor et al., <i>Science</i> 251: 767-777, 1991	
	60	Foster et al., <i>Pharmacol. Ther.</i> 94: 253-264, 2002	
	61	Freese et al., <i>Biochem. Pharmacol.</i> 40(10): 2189-2199, 1990	
	62	Geftter et al., <i>Somatic Cell Genet.</i> 3(2): 231-236, 1977	
	63	Goeddel et al., <i>Nucleic Acids Res.</i> 8(18): 4057- 4074, 1980	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/550,721
	Filing Date	03/26/2004
	First Named Inventor	Michael Rolph
	Art Unit	Unknown
	Examiner Name	Unknown
Sheet 4 of 6	Attorney Docket Number	007193-12

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or county where published.	T ²
	64	Gorziglia et. al., <i>J. Virol.</i> 66(7): 4407-4412, 1992	
	65	Helseth et al., <i>J. Virol.</i> 64(5): 2416-2420, 1990	
	66	Hodgson, <i>Bio/Technology</i> 9: 19-21, 1991	
	67	Holgate et al., <i>Clin. Exp. Alergy</i> 29(2): 90-95, 1999	
	68	Hotamisligil et al., <i>Science</i> 274(5291):1377-1379, 1996	
	69	Johnson et al., <i>J. Virol.</i> 66(5): 2952-2965, 1992	
	71	Jordan et al., <i>J. Clin. Invest.</i> 104(8): 1061-1069, 1999	
	72	Kennett et al., <i>Monoclonal Antibodies and Hybridomas: A New Dimension in Biological Analyses</i> , pp 376-384, Plenum Press, New York, 1980	
	73	Kim et al, Abstract 227-OR American Diabetes Association Annual Meeting, 2003	
	74	Kohler, <i>Eur. J. Immunol.</i> 6(7): 511-519, 1976	
	75	Köhler, <i>Nature</i> 256: 495-497, 1975	
	76	Kozal et al. <i>Nature Medicine</i> 2: 753-759, 1996	
	77	Kozbor et al., <i>Methods in Enzymology</i> 121: 140, 1986	
	78	Lawn et al., <i>Nucleic Acids Res.</i> 9(22): 6103-6114, 1981	
	79	Leckie et al., <i>Lancet</i> 356: 2144-2148, 2000	
	80	Lewis et al., <i>J. Pathol.</i> 195: 66-71, 2001	
	81	Mackay et al., <i>Nucleic Acids Res</i> 30(6): 1292-1305, 2002	
	82	Madsen, P. et al., "Molecular cloning and expression of a novel keratinocyte protein (psoriasis-associated fatty acid-binding protein [PA-FABP]) that is highly up-regulated in psoriatic skin and that shares similarity to fatty acid-binding proteins," <i>J Invest Dermatol</i> 1992, 99(3):299-305. (Abstract and Sequence Listing)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/550,721
	Filing Date	03/26/2004
	First Named Inventor	Michael Rolph
	Art Unit	Unknown
	Examiner Name	Unknown
Sheet 5 of 6	Attorney Docket Number	007193-12

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. *	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or county where published.	T ²
	83	Madzak <i>et al.</i> , <i>J. Gen. Virol.</i> 73: 1533-1536, 1992	
	84	Maeda <i>et al.</i> , <i>Diabetes</i> 52:300-307, 2003	
	85	Mann <i>et al.</i> , <i>J. Virol.</i> 54(2): 401-407, 1985	
	86	Margolskee, <i>Curr. Top., Microbiol. Immunol.</i> 158: 67-95, 1992	
	87	Miller, A.D. <i>et al.</i> , <i>J. Virol.</i> 62(11): 4337-4345, 1988	
	88	Miller, A.D. <i>et al.</i> , <i>Mol. Cell. Biol.</i> 5(3): 431-437, 1985;	
	89	Miller, <i>Curr. Top. Microbiol. Immunol.</i> 158: 1-24, 1992;	
	90	Moss, <i>Curr. Top. Microbiol. Immunol.</i> 158:25-38 (1992)	
	91	Moss, <i>Proc. Natl. Acad. Sci. USA</i> 93(21): 11341-11348, 1996	
	92	Mullis <i>et al.</i> , <i>Quant. Biol.</i> 51: 263-273, 1987; Erlich, eds., PCR Technology, Stockton Press, NY, 1989	
	93	Munder <i>et al.</i> , <i>Appl. Microbiol. Biotechnol.</i> 52: 311-320, 1999	
	94	Muzyczka, <i>Curr. Top. Microbiol. Immunol.</i> 158: 97-129, 1992	
	95	Naldini <i>et al.</i> , <i>Science</i> 272: 263-267, 1996	
	96	O'Reilly <i>et al.</i> , <i>Biotechniques</i> 25: 824-830, 1998	
	97	Ohi <i>et al.</i> , <i>Gene</i> 89: 279-282, 1990	
	98	Page <i>et al.</i> , <i>J. Virol.</i> 64(11): 5270-5276, 1990	
	99	Petropoulos <i>et al.</i> , <i>J. Virol.</i> 66(6): 3391-3397, 1992	
	100	Punnonen <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> 90(8): 3730-3740, 1993	
	101	Quantin <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> 89(7): 2581-2584, 1992	
	102	Rosenfeld <i>et al.</i> , <i>Cell</i> 68: 143-155, 1992	
	103	Rozen, <i>Methods Mol. Biol.</i> 132: 365-386, 2000	
	104	Russell <i>et al.</i> , <i>Nature Genetics</i> 18: 325-330, 1998	
	105	Scheidner <i>et al.</i> , <i>Nature Genetics</i> 18: 180-183, 1998	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/550,721
	Filing Date	03/26/2004
	First Named Inventor	Michael Rolph
	Art Unit	Unknown
	Examiner Name	Unknown
Sheet 6 of 6	Attorney Docket Number	007193-12

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or county where published.	T ²
	106	Shimada <i>et al.</i> , <i>J. Clin. Invest.</i> 88: 1043-1047, 1991	
	107	Shulman <i>et al.</i> , <i>Nature</i> 276: 269-270, 1978	
	108	Sorge <i>et al.</i> , <i>Mol. Cell. Biol.</i> 4(9): 1730-1737, 1984	
	109	Stratford-Perricaudet <i>et al.</i> , <i>Hum. Gene Ther.</i> 1: 241-256, 1990	
	110	Summerton <i>et al.</i> , <i>Antisense and Nucleic Acid Drug Development</i> 7: 187-195, 1997	
	111	Trowbridge, <i>J. Exp. Med.</i> 148(1): 313-323, 1978	
	112	Volk <i>et al.</i> , <i>J. Virol.</i> 42(1): 220-227, 1982	
	113	Walker, <i>J. Biochem. Mol. Toxicology</i> 15(3): 121-127, 2001	
	114	Wells, <i>Methods Enzymol.</i> 202: 2699-2705, 1991	
	115	Wills-Karp, <i>Annu. Rev. Immunol.</i> 17: 255-281, 1999	
	116	Wilkinson <i>et al.</i> , <i>Nucleic Acids Res.</i> 20(9): 2233-2239, 1992	
	117	Young <i>et al.</i> , <i>Nat. Biotechnol.</i> 16: 946-950, 1998	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--